公开(公告)号：US11708396B2

公开(公告)日：2023-07-25

申请号：US17162061

申请日：2021-01-29

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  Tirtha Chakraborty ,  Joshua P. Frederick ,  Matthias John ,  Antonin De Fougerolles

IPC: A61K48/00 ,  C07K14/47 ,  C12N15/85 ,  C12N15/113 ,  A61K31/7105 ,  A61K31/711 ,  A61K38/00

CPC classification number: C07K14/47 ,  A61K31/711 ,  A61K31/7105 ,  A61K48/0058 ,  C12N15/113 ,  C12N15/85 ,  A61K38/00 ,  C12N2310/141

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of signal-sensor polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US11603399B2

公开(公告)日：2023-03-14

申请号：US15591820

申请日：2017-05-10

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  Eric Yi-Chun Huang ,  Tirtha Chakraborty ,  Sayda M. Elbashir

IPC: C07K14/76 ,  C12N15/67 ,  C07K14/50 ,  C07K14/535 ,  C07K14/59 ,  C07K14/605 ,  C07K14/61 ,  C07K14/765 ,  C07K16/00 ,  A61K48/00

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of long-lived polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US20180086816A1

公开(公告)日：2018-03-29

申请号：US15591820

申请日：2017-05-10

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  Eric Yi-Chun Huang ,  Tirtha Chakraborty ,  Sayda M. Elbashir

IPC: C07K14/76 ,  C07K14/61 ,  C07K14/50 ,  C07K14/535 ,  C07K14/59 ,  C07K14/605 ,  C12N15/67 ,  C07K14/765 ,  C07K16/00

CPC classification number: C07K14/76 ,  A61K48/00 ,  C07K14/50 ,  C07K14/535 ,  C07K14/59 ,  C07K14/605 ,  C07K14/61 ,  C07K14/765 ,  C07K16/00 ,  C07K2319/00 ,  C12N15/67

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of long-lived polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US10138507B2

公开(公告)日：2018-11-27

申请号：US14777190

申请日：2014-03-13

Applicant: ModernaTX, Inc.

Inventor： Stephane Bancel ,  William Joseph Issa ,  John Grant Aunins ,  Tirtha Chakraborty

IPC: C12P19/34 ,  C12Q1/68 ,  C12N15/10 ,  C12Q1/6865

Abstract: Described are methods for production of RNA transcripts using a non-amplified, linearized DNA template in an in vitro transcription reaction. Enzymatic 5′ capping and oligo dT purification can also be included in the methods.

公开(公告)号：US12246030B2

公开(公告)日：2025-03-11

申请号：US18167984

申请日：2023-02-13

Applicant: ModernaTX, Inc.

Inventor： Stephen Hoge ,  Tirtha Chakraborty ,  Gilles Besin ,  Ruchi Jain

IPC: C07H21/04 ,  A61K9/00 ,  A61K9/127 ,  A61K31/7115 ,  C12N15/113 ,  C12N15/67

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

公开(公告)号：US10772975B2

公开(公告)日：2020-09-15

申请号：US15790246

申请日：2017-10-23

Applicant: ModernaTX, Inc.

Inventor： Stephane Bancel ,  Tirtha Chakraborty ,  Antonin De Fougerolles ,  Sayda M. Elbashir ,  Matthias John ,  Atanu Roy ,  Susan Whoriskey ,  Kristy M. Wood ,  Paul Hatala ,  Jason P. Schrum ,  Kenechi Ejebe ,  Jeff Lynn Ellsworth ,  Justin Guild

IPC: C07K14/535 ,  A61K38/17 ,  A61K48/00 ,  C12N15/85 ,  C07K14/47 ,  C07K14/62 ,  A61K31/7115 ,  C12N9/88 ,  A61K9/127 ,  C12N15/11 ,  C07K14/705 ,  C07K14/505 ,  C12N9/64 ,  C12N9/10 ,  C12N9/00 ,  C12N9/42 ,  C12N15/87 ,  C12P13/04 ,  A61K38/45 ,  C07K14/005 ,  C12N9/16 ,  C12N9/24 ,  C12N15/52 ,  C07K14/435 ,  C12P21/00 ,  C07K14/485 ,  C07H21/02 ,  C07K14/475 ,  C07K14/495 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/745 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  C12N9/12 ,  C12N9/68 ,  A61K47/54 ,  A61K9/14 ,  A61K9/51 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/48 ,  C07K14/515 ,  C07K16/00 ,  A61K31/7088 ,  A61K47/10 ,  A61K38/00

Abstract: The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5′-cap, 5′-UTR, a 3′-UTR, and a poly-A region with at least 100 nucleotides.

公开(公告)号：US09828416B2

公开(公告)日：2017-11-28

申请号：US14750004

申请日：2015-06-25

Applicant: ModernaTX, Inc.

Inventor： Stephane Bancel ,  Tirtha Chakraborty ,  Antonin de Fougerolles ,  Sayda M. Elbashir ,  Matthias John ,  Atanu Roy ,  Susan Whoriskey ,  Kristy M. Wood ,  Paul Hatala ,  Jason P. Schrum ,  Kenechi Ejebe ,  Jeff Lynn Ellsworth ,  Justin Guild

IPC: C12N15/85 ,  A61K31/7088 ,  A61K47/48 ,  C07K14/535 ,  A61K48/00 ,  C12N15/88 ,  A61K9/127 ,  A61K9/50 ,  C07K19/00 ,  A61K38/18 ,  A61K38/19 ,  A61K38/48 ,  C07K14/47 ,  A61K9/14 ,  A61K38/17 ,  A61K47/10 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K39/395 ,  C07K14/475 ,  C07K14/505 ,  C07K14/525 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K14/75 ,  C07K16/28 ,  C07K16/32 ,  C12N9/02 ,  C12N9/64 ,  A61K9/00

CPC classification number: C07K14/535 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/1277 ,  A61K9/14 ,  A61K9/5031 ,  A61K31/7088 ,  A61K38/1767 ,  A61K38/1816 ,  A61K38/1866 ,  A61K38/191 ,  A61K38/193 ,  A61K38/212 ,  A61K38/215 ,  A61K38/36 ,  A61K38/363 ,  A61K38/44 ,  A61K38/4833 ,  A61K38/4846 ,  A61K39/3955 ,  A61K47/10 ,  A61K47/54 ,  A61K47/542 ,  A61K48/00 ,  A61K48/0033 ,  A61K48/0066 ,  A61K48/0075 ,  C07K14/47 ,  C07K14/475 ,  C07K14/505 ,  C07K14/525 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K14/75 ,  C07K16/2887 ,  C07K16/32 ,  C07K19/00 ,  C12N9/0069 ,  C12N9/644 ,  C12N15/85 ,  C12N15/88 ,  C12N2840/00 ,  C12Y113/12007 ,  C12Y304/21005 ,  C12Y304/21022

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US12023371B2

公开(公告)日：2024-07-02

申请号：US17127435

申请日：2020-12-18

Applicant: ModernaTX, Inc.

Inventor： Tirtha Chakraborty ,  Stephane Bancel ,  Stephen G. Hoge ,  Atanu Roy ,  Antonin De Fougerolles ,  Noubar B. Afeyan

IPC: A61K39/00 ,  C12N15/67

CPC classification number: A61K39/00 ,  C12N15/67

Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.

公开(公告)号：US11590157B2

公开(公告)日：2023-02-28

申请号：US17036374

申请日：2020-09-29

Applicant: ModernaTX, Inc.

Inventor： Stephen Hoge ,  Tirtha Chakraborty ,  Gilles Besin ,  Ruchi Jain

IPC: C07H21/02 ,  A61K31/7115 ,  C12N15/67 ,  A61K9/00 ,  A61K9/127 ,  C12N15/113

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

公开(公告)号：US11027025B2

公开(公告)日：2021-06-08

申请号：US14903869

申请日：2014-07-11

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  Eric Yi-Chun Huang ,  Tirtha Chakraborty

IPC: A61K48/00 ,  C12N15/90 ,  C12N9/16 ,  C12N15/11

Abstract: The present invention relates to compositions comprising and methods of using synthetic polynucleotides, e.g., modified mRNA, encoding CRISPR related proteins including dCAS9 and synthetic sgRNAs targeting a gene of interest.